Covid-19 Vaccine Trials

09/22/2020

Vaccines are important at any age. Learn why in 30 seconds. (Courtesy, Alliance for Aging Research)

09/22/2020

Before a vaccine is developed it undergoes rigorous testing. Vaccines are subject to even tougher standards than medicines - more people are included in clinical trials and safety standards are very high. (Courtesy Vaccines Today)

09/20/2020

https://www.washingtonpost.com/health/2020/08/27/large-us-covid-19-vaccine-trials-are-halfway-enrolled-lag-participant-diversity/

Moderna and Pfizer are halfway to signing up the 30,000 participants they need for the final stage of testing. But only about a fifth are Black or Hispanic.

09/20/2020

https://www.cbsnews.com/news/covid-19-vaccine-trials-minorities-recruitment/

09/20/2020

Around $10bn is being spent on finding a vaccine for coronavirus—it’s not nearly enough. And even when a covid-19 vaccine is found how should it be distributed fairly? Our experts answer your questions. (Courtesy The Economist)

09/20/2020

https://www.who.int/news-room/detail/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility

09/20/2020

Details of Clinical Trials of vaccines including, COVID 19 Vaccine development (against Coronavirus). This video will give a detailed approach for different platforms used to make COVID -19 vaccine, (DNA and RNA protein instructions), It also describes different companies which are involved in new technology vaccine development (Vaccine Rapid Response Technology). A detailed description of trials for general vaccine is also available, with all the phases of vaccine development like, Exploratory phase, Phase I, Combined phase I/2, Phase 2 and Phase 3, followed by marketing. (Courtest CLINICAL GYAN)

09/20/2020

https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3)4b6debde1bdc4a85ae67d4ce578be1bf.pdf?sfvrsn=57c0b234_3&download=true

09/20/2020

There are currently over 169 COVID-19 vaccine candidates under development, with 26 of these in the human trial phase. WHO is working in collaboration with scientists, business, and global health organizations through the ACT Accelerator to speed up the pandemic response. When a safe and effective vaccine is found, COVAX (led by WHO, GAVI and CEPI) will facilitate the equitable access and distribution of these vaccines to protect people in all countries. People most at risk will be prioritized.

The world is in the midst of a COVID-19 pandemic. As WHO and partners work together on the response -- tracking the pandemic, advising on critical interventions, distributing vital medical supplies to those in need--- they are racing to find a vaccine.

09/19/2020

Humankind has never had a more urgent task than creating broad immunity for coronavirus. Realistically, if we’re going to return to normal, we need to develop a safe, effective vaccine—and we need to do it faster than we’ve ever developed a vaccine before.

09/19/2020

More than 30 biotech and pharmaceutical companies around the world are racing to develop a safe Covid-19 vaccine. The process is moving quickly with several vaccine candidates entering late-stage trials in a matter of months. Two of the companies developing a vaccine — Pfizer and Moderna — are utilizing a promising new technology called messenger RNA. Watch the video to learn why experts believe this vaccination method could be a game-changer for getting back to normal.

09/19/2020

Vaccines prepare the immune system to fight infections and prevent illnesses. Certain cells of the immune system produce antibodies (special proteins) that recognize viruses and other pathogens (things that cause disease) and make them harmless.

The vaccine being tested in this study is called mRNA-1273. The study team is testing if the vaccine can help the immune system produce effective antibodies against the SARS-CoV-2 virus so that, in case of infection, the virus does not cause illness.

Typical vaccines for viruses are made from a weakened or inactive virus, but mRNA-1273 is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies to fight the virus.

The vaccine cannot cause infection or make someone sick with COVID-19. Since March 2020, more than 300 people have received the vaccine so far with no serious side effects. More than 1,900 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe, and Australia.